SCHEMBL371005

SCHEMBL371005

CCOC(=O)c1sc(C(=O)OC(C)(C)C)nc1-c1cn(Cc2ccc(OC)cc2)nc1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PTPN11 Q06124 1/20 0.39
MKNK2 Q9HBH9 1/20 0.38
RXFP1 Q9HBX9 2/20 0.38
DHODH Q02127 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15182514 0.77 CDC7 (0.46) CDC7DBF4ALDH1A1KDM4EHPGD
SCHEMBL6837459 0.76 RXFP1 (0.42) CDC7DBF4ALDH1A1KDM4EHPGD
SCHEMBL6837270 0.75 LCK (0.38) ALDH1A1KDM4ENPSR1GAARXFP1
SCHEMBL370309 0.74 ALDH1A1 (0.45) CDC7DBF4ALDH1A1KDM4EHPGD
SCHEMBL6837480 0.73 RXFP1 (0.42) ALDH1A1KDM4ENPSR1MKNK2RXFP1
SCHEMBL15182515 0.73 MEN1 (0.42) ALDH1A1KDM4EHPGDNPC1MAPT
SCHEMBL6837466 0.73 LCK (0.36) NPSR1MKNK2RXFP1MAPTKDM1A
SCHEMBL6837114 0.72 MKNK2 (0.42) ALDH1A1KDM4EHPGDNPSR1USP2
SCHEMBL15182528 0.72 CDC7 (0.40) CDC7DBF4ALDH1A1KDM4EHPGD
SCHEMBL3356514 0.70 MAPT (0.46) ALDH1A1KDM4EHPGDNPSR1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 CDC7 4513/4885DBF4 3652/4885ALDH1A1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.